The trial’s primary endpoint was a ≥1 CRN fibrosis stage improvement with no worsening of steatohepatitis compared with placebo at week 72. “Although emricasan did not have the
The further positive data from the DREAMM-1 study, which is based on results of the pre-specified interim analysis, showed the durability and depth of response of GSK2857916 anti-BCMA
The post GSK’s anti-BCMA antibody-drug conjugate improves ORR in cancer study appeared first on Pharmaceutical Business review.
Other investors participating in the round include existing investors Frazier Healthcare Partners, Amgen Ventures, and MRL Ventures Fund as well as HighLight Capital, Pharmaron and Greenspring Associates. Dr.
The post Imago BioSciences announces $40m Series B financing led by Omega Funds appeared first on Pharmaceutical Business review.
A group of researchers at the Cambridge Institute for Medical Research found that the epigenetic protein delayed the development of AML. However, the epigenetic protein was found to
The post Study suggests epigenetic protein as new therapeutic target in AML appeared first on Pharmaceutical Business review.
The collaboration, originally announced in February 2015, is focused on discovering, developing and commercializing novel biologic therapeutics across a wide range of therapeutic areas. Under the terms of
The post Merck, NGM Bio extend multi-year strategic collaboration appeared first on Pharmaceutical Business review.
Pfizer has paid around €45m ($51m) to purchase a 15% equity interest in Vivet Therapeutics, and will pay up to €560m that includes option exercise payment and certain
The post Pfizer secures option to buy Vivet Therapeutics in €560m deal appeared first on Pharmaceutical Business review.
In line with the partnership with Janssen Pharmaceutica NV, Mundipharma now exclusively distributes and markets these treatments across 18 countries in the European Economic Area (EEA) and Switzerland.
The post Mundipharma launches Invokana and Vokanamet in Norway for treatment of type 2 diabetes appeared first on Pharmaceutical Business review.
The alliance has notified health authorities and trial investigators of the decision to discontinue the trial. The decision was based on several emerging factors since the trial’s initiation,
The post Merck KGaA, Pfizer discontinue phase III JAVELIN ovarian PARP 100 trial appeared first on Pharmaceutical Business review.
The public-private partnership between Evotec and GARDP will strive to address the increasing threat of antimicrobial resistance (AMR). It will combine GARDP’s clinical expertise and Evotec’s drug discovery
The post Evotec, GARDP partner to tackle antimicrobial resistance threat appeared first on Pharmaceutical Business review.
Zulresso is claimed to be the first and only medicine secured approval to treat PPD, which is the most common medical complication of childbirth. The medicine is an
The post Sage Therapeutics gets FDA nod for Zulresso to treat postpartum depression appeared first on Pharmaceutical Business review.
News from Twitter
We are saddened to share the news of the passing of Dr. Yves Cotrel. A pioneer in modern spine surgery, Dr. Cotrel's company Sofamor, was the foundation for what would become Medtronic Spine. Dr. Cotrel's contributions will live on for years to come. Condolences to his family. pic.twitter.com/JJ1Z…
The 44th edition of Arab Health is officially now open. #ArabHealth2019 runs until the 31st of January 2019 at the Dubai World Trade Centre and the Conrad Dubai from 10 am to 6 pm. Find out more on our website or download the Arab Health 2019 show app: bit.ly/2n3Z5Q pic.twitter.com/oasI…
Cancer is not a ‘one size fits all,’ nor is the way we treat it. We are working to better understand the different ways a cancer can mutate so we can discover new approaches to treat some of the most difficult-to-treat types of the disease. #ReimagineMedicine #ESMO18 pic.twitter.com/41QL…
Large-vessel giant cell arteritis: diagnosis, monitoring and management | Rheumatology | Oxford Academic academic.oup.com/rhe…
Scientists have made an unexpected discovery while investigating the triggering factors of #ColonCancer: Cell stress in combination with an altered microbiota in the colon drives tumor growth. Learn more: ow.ly/JxtK30meLTY pic.twitter.com/U51Q…
If you are in Dallas attending the AAFPRS 12th International Symposium of Facial Plastic Surgery don’t miss out on this Breakfast Symposium tomorrow morning with Dr. William Binder that is sponsored by Implantech! #implantech #superiorpatientaesthetics #implantechrewards #aafprs pic.twitter.com/HCzK…
With #CARTcell therapy, an inactive virus programs T cells with new genetic information to help recognize specific antigens found on normal cells and certain blood cancer cells. As the CAR-T cells multiply, new copies also gain this ability. #CARTCellStory pic.twitter.com/Xuoh…
Make plans to visit the Integra LifeSciences Booth# 919 during Plastic Surgery The Meeting September 28th - October 1st. #Integra_LifeSciences #DurableIsBeautiful #PSTM18 #ASPS #PlasticSurgery pic.twitter.com/8QGv…
We are live at #NASS2018 stand 2649. Get hands-on with the world's leading surgical #simulator in #VR with #haptics and experience the future of surgical training. #wearefundamental fundamentalsurgery.c… pic.twitter.com/NgzA…
Great things happening at Tissue Regenix! Plan to visit our booth at the AAOS meeting in New Orleans, under the CellRight Technologies banner #5413. @AAOS1
All evaluation cases for the new Corin Dual Mobility option for the Trinity Acetabular cup system have now been completed and we're looking forward to the full launch. Click lnkd.in/g8ariEY for details #orthopaedics #technology #totalhip #uniquehip pic.twitter.com/SPsy…
#cardiovascular news CorFlow Presents Fundamental New Insights into the Coronary Microcirculation at ACC - CorFlow Therapeutics AG corflowtherapeutics.… today announced that the company will present fundamental new insights into the coronary microci... ow.ly/OlaG50gAElO
Our very best and up-to-date selection of healthcare Industries' News (Products, Markets, Companies, R&D, Technology, Opportunities, Investment & Finance...).
Read at Healthcare News